



Curriculum Vitae

Personal information **chloé Wyndham Thomas**

Work experience

1. Employer: Federal Agency for Medicines and Health Products

- Start date: 012025
- End date:
- Position: Pharmacovigilance assessor
- Activities: Vaccine safety
- Country: Belgium

2. Employer: P95

- Start date: 052022
- End date: 122024
- Position: Senior epidemiologist
- Activities: COVID-19 and RSV vaccine effectiveness studies (id.DRIVE); Meeting rapporteur for the Adult Immunization Board
- Country: Belgium

3. Employer: Sciensano (Scientific institute of Public Health)

- Start date: 022018
- End date: 052022
- Position: Medical epidemiologist/Scientific collaborator
- Activities: Surveillance of vaccine-preventable diseases; National contact point for Belgium, ECDC Vaccine preventable disease; Member of Belgium National Immunization Technical Advisory Group (NITAG); Alternate member of the EU/EEA NITAG Collaboration; Secretariat for Belgium's National Certification Committee for the elimination of Polio; Member National Certification Committee for the elimination of Measles & Rubella; Member of the Belgian Task Force "Operationalisation of the Covid-19 Immunisation Strategy" and coordinator of its working group "Surveillance" [112020- 122022]; Project manager for LINK-VACC : Linking of registers for COVID-19 vaccine surveillance [102020-122022]
- Country: Belgium

4. Employer: Erasme University Hospital

- Start date: 102014
- End date: 022018
- Position: Resident doctor
- Activities: Internal medicine specialist for AIDS Reference Centre and Immunodeficiency Treatment Unit
- Country: Belgium

5. Employer: Erasme University Hospital

- Start date: 042014
- End date: 102014
- Position: Medical doctor - Internal Medicine specialist candidate
- Activities: Infectious and tropical diseases clinic
- Country: Belgium

6. Employer: Université Libre de Bruxelles

- Start date: 102011
- End date: 042014
- Position: PhD fellow in medical sciences
- Activities: PhD thesis "Screening for latent M. tuberculosis infection in HIV-positive patients residing in low tuberculosis incidence settings: Investigation of the current practices and identification of clinical- and immune-based strategies for improvement"
- Country: Belgium

7. Employer: rotation in several Brussels-based university hospitals - St Pierre University Hospital, Erasme University Hospital, IRIS SUD

- Start date: 102011
- End date: 102011
- Position: Medical doctor - Internal Medicine specialist candidate
- Activities: Internal medicine
- Country: Belgium

Education and training

1. Subject: Université Libre de Bruxelles

- Start date: 102011
- End date: 042014
- Qualification: Masters and Doctorate (PhD) in medical sciences
- Country: Belgium

2. Subject: Université Libre de Bruxelles

- Start date: 102007
- End date: 092014
- Qualification: Complementary Masters in Internal medicine
- Country: Belgium

2. Subject: Université Libre de Bruxelles

- Start date: 102000
- End date: 092007
- Qualification Bachelor and Masters in Medicine
- Country: Belgium

Additional courses, workshops and certifications :

- Alumni Refresher Vaccinology Course, ICAVT (Online, June 2023).
- Advanced Course in Vaccinology, ADVAC (May 2021)
- The science of using science to support policy making, ECDC Winter workshop (Stockholm, 2020)
- Advanced Course in Basic & Clinical Immunology; FOCIS (Paris, 2016)
- New York Course in HIV-Hepatitis management (New York, 2016)
- Advances in Primary Immunodeficiency, CID winter school (London, 2016)
- Certification in Good clinical practice (Belgium, 2015).
- Inter-university certificate in infectious diseases & clinical microbiology (Belgium, 2013-2014)
- Advanced HIV Course, EACS (Aix-en-Provence, 2014)
- Writing the protocol for a Cochrane Systematic Review, EBM (Leuven, 2013)
- Advanced course in Internal Medicine, BSIM (Brussels, 2011-2013)
- Summer school of Translational Immunology, COST (Belgrade, 2012)

Additional information

Publications

- de Munter L, Meeraus W, Dwivedi A, Mitratza M, Wyndham-Thomas C, Carty L, Ouwens M, Hartig-Merkel W, Drikite L, Rebry G, Casas I, Mira-Iglesias A, Icardi G, Otero-Romero S, Baumgartner S, Martin C, Holemans X, Ten Kate GL, Bollaerts K, Taylor S. Effectiveness of the AZD1222 vaccine against COVID-19 hospitalization in Europe: final results from the COVIDRIVE test-negative case-control study. *Eur J Public Health*. 2025 Jan 21:ckae219.
- Boccalini S, Bechini A, Del Riccio M, Weinberger B, Wysocki J, Martinelli D, Wichmann O, Likk T, Hendrickx G, Van Damme P, Wyndham-Thomas C, Bonanni P, Pattyn J. Strategies for introducing and implementing vaccines for adults into national immunization programs in Europe: Good practices and key insights of the adult immunization board meeting. *Hum Vaccin Immunother*. 2025 Dec;21(1):2451487.
- Bechini A, Boccalini S, Del Riccio M, Pattyn J, Hendrickx G, Wyndham-Thomas C, Gabutti G, Maggi S, Ricciardi W, Rizzo C, Costantino C, Vezzosi L, Guida A, Morittu C, Van Damme P, Bonanni P. Overview of adult immunization in Italy: Successes, lessons learned and the way forward. *Hum Vaccin Immunother*. 2024 Dec 31;20(1):2411821
- Bollaerts K, Wyndham-Thomas C, Miller E, Izurieta HS, Black S, Andrews N, Rubbrecht M, Van Heuverswyn F, Neels P. The role of real-world evidence for regulatory and public health decision-making for Accelerated Vaccine Deployment- a meeting report. *Biologicals*. 2024 Feb;85:101750.
- Cavillot L, van Loenhout JAF, Devleeschauwer B, Wyndham-Thomas C, Van Oyen H, Ghattas J, Blot K, Van den Borre L, Billuart M, Speybroeck N, De Pauw R, Stouten V, Catteau L, Hubin P. Sociodemographic and socioeconomic disparities in COVID-19 vaccine uptake in Belgium: a nationwide record linkage study. *J Epidemiol Community Health*. 2023 Dec 26;78(3):176-83.
- Meeraus W, de Munter L, Gray CM, Dwivedi A, Wyndham-Thomas C, Ouwens M, Hartig-Merkel W, Drikite L, Rebry G, Carmona A, Stuurman AL, Chi Nguyen TY, Mena G, Mira-Iglesias A, Icardi G, Otero-Romero S, Baumgartner S, Martin C, Taylor S, Bollaerts K. Protection against COVID-19 hospitalisation conferred by primary-series vaccination with AZD1222 in non-boostered individuals: first vaccine effectiveness results of the European COVIDRIVE study and meta-regression analysis. *Lancet Reg Health Eur*. 2023 Jul 1;31:100675.
- Braeye T, van Loenhout JAF, Brondeel R, Stouten V, Hubin P, Billuart M, Chung PYJ, Vandromme M, Wyndham-Thomas C, Blot K, Catteau L. COVID-19 vaccine effectiveness against symptomatic infection and hospitalisation in Belgium, July 2021 to May 2022. *Euro Surveill*. 2023 Jun;28(26):2200768.
- Braeye T, Catteau L, Brondeel R, van Loenhout JAF, Proesmans K, Cornelissen L, Van Oyen H, Stouten V, Hubin P, Billuart M, Djiena A, Mahieu R, Hammami N, Van Cauteren D, Wyndham-Thomas C. Vaccine effectiveness against transmission of alpha, delta and omicron SARS-CoV-2-infection, Belgian contact tracing, 2021-2022. *Vaccine*. 2023 May 11;41(20):3292-3300.
- Braeye T, Catteau L, Brondeel R, van Loenhout JAF, Proesmans K, Cornelissen L, Van Oyen H, Stouten V, Hubin P, Billuart M, Djiena A, Mahieu R, Hammami N, Van Cauteren D, Wyndham-Thomas C. Vaccine effectiveness against onward transmission of SARS-CoV2-infection by variant of concern and time since vaccination, Belgian contact tracing, 2021. *Vaccine*. 2022 May 11;40(22):3027-3037.
- Stouten V, Hubin P, Haarhuis F, van Loenhout JAF, Billuart M, Brondeel R, Braeye T, Van Oyen H, Wyndham-Thomas C, Catteau L. Incidence and Risk Factors of COVID-19 Vaccine Breakthrough Infections: A Prospective Cohort Study in Belgium. *Viruses*. 2022 Apr 13;14(4):802.
- Jacquinet S, Mattheus W, Quoilin S, Wyndham-Thomas C, Martin C, Van der Linden D, Mulder A, Frère J, Schirvel C. Outbreak of invasive meningococcal disease caused by a meningococcus serogroup B in a nursery school, Wallonia, Belgium, 2018. *Euro Surveill*. 2022 Mar;27(9):2100224.
- Van Goethem N, Serrien B, Vandromme M, Wyndham-Thomas C, Catteau L, Brondeel R, Klamer S, Meurisse M, Cuyper L, André E, Blot K, Van Oyen H. Conceptual causal framework to assess the effect of SARS-CoV-2 variants on COVID-19 disease severity among hospitalized patients. *Arch Public Health*. 2021 Oct 25;79(1):185.
- Braeye T, Cornelissen L, Catteau L, Haarhuis F, Proesmans K, De Ridder K, Djiena A, Mahieu R, De Leeuw F, Dreuw A, Hammami N, Quoilin S, Van Oyen H, Wyndham-Thomas C, Van Cauteren D. Vaccine effectiveness against infection and onwards transmission of COVID-19: Analysis of Belgian contact tracing data, January-June 2021. *Vaccine*. 2021 Sep 15;39(39):5456-5460.
- Van Goethem N, Vilain A, Wyndham-Thomas C, Deblonde J, Bossuyt N, Lernout T, Gonzalez JR, Quoilin S, Melis V, Van Beckhoven D. Correction to: Rapid establishment of a national surveillance of COVID-19 hospitalizations in Belgium. *Arch Public Health*. 2021 Aug 18;79(1):147. Erratum for: *Arch Public Health*. 2020 Nov 18;78(1):121.
- Catteau L, Dauby N, Montourcy M, Bottieau E, Hautekiet J, Goetghebeur E, van Ierssel S, Duysburgh E, Van Oyen H, Wyndham-Thomas C, Van Beckhoven D; Belgian Collaborative Group on COVID-19 hospital surveillance. Low-dose Hydroxychloroquine Therapy and Mortality in Hospitalized Patients with COVID-19: A Nationwide Observational Study of 8075 Participants. *Int J Antimicrob Agents*. 2020 Aug 24:106144.
- Desmet S, Lagrou K, Wyndham-Thomas C, Braeye T, Verhaegen J, Maes P, Fieuws S, Peetermans WE, Blumental S. Dynamic changes in paediatric invasive pneumococcal disease after sequential switches of conjugate vaccine in Belgium: a national retrospective observational study. *Lancet Infect Dis*. 2020 Jul 20:S1473-3099(20)30173-0.
- Hoxha A, Wyndham-Thomas C, Klamer S, Dubourg D, Vermeulen M, Hammami N, Cornelissen L. Asymptomatic SARS-CoV-2 infection in Belgian long-term care facilities. *Lancet Infect Dis*. 2020 Jul 3:S1473-3099(20)30560-0.

- Van Beckhoven D, Florence E, De Wit S, Wyndham-Thomas C, Sasse A, Van Oyen H, Macq J; Belgian Research on AIDS, HIV Consortium (BREACH). Incidence rate, predictors and outcomes of interruption of HIV care: nationwide results from the Belgian HIV cohort. *HIV Med.* 2020 Jul 5.
- Cornelissen L, Grammens T, Leenen S, Schirvel C, Hutse V, Demeester R, Swennen B, Asikainen T, Wyndham-Thomas C. High number of hospitalisations and non-classical presentations: lessons learned from a measles outbreak in 2017, Belgium. *Epidemiol Infect.* 2020 Feb 24;148:e35.
- Litzroth A, Suin V, Wyndham-Thomas C, Quoilin S, Muyltermans G, Vanwolleghem T, Kabamba-Mukadi B, Verburgh V, Jacques M, Van Gucht S, Hutse V. Low hepatitis C prevalence in Belgium: implications for treatment reimbursement and scale up. *BMC Public Health.* 2019 Jan 8;19(1):39.
- Wyndham-Thomas C, Grammens T, Litzroth A, Sizaire V, Boon N, Muyltermans G, Lernout T. Surveillance épidémiologique des maladies infectieuses à prévention vaccinale (vaccins inclus dans le calendrier vaccinal belge). Synthèse annuelle 2017. Bruxelles, Belgique : Sciensano; 2019. Numéro de rapport : D/2019/14.440/22. Disponible en ligne : <https://epidemio.wiv-isp.be/ID/Pages/Publications.aspx>
- Litzroth A, Suin V, Wyndham-Thomas C, Quoilin S, Muyltermans G, Vanwolleghem T, Kabamba-Mukadi B, Verburgh V, Jacques M, Van Gucht S, Hutse V. Low hepatitis C prevalence in Belgium: implications for treatment reimbursement and scale up. *BMC Public Health.* 2019 Jan 8;19(1):39. doi: 10.1186/s12889-018-6347-z.
- Wyndham-Thomas C, Dirix V, Goffard JC, Henrard S, Wanlin M, Callens S, Mascart F, Van Vooren JP. 2018 Belgian guidelines for the screening for latent tuberculosis in HIV-infected patients. *Acta Clin Belg.* 2018 Jul 23;1-10. doi: 10.1080/17843286.2018.1494669.
- Martin C, Castaigne C, Vierasu I, Garcia C, Wyndham-Thomas C, de Wit S. Prospective Serial FDG PET/CT During Treatment of Extrapulmonary Tuberculosis in HIV-Infected Patients: An Exploratory Study. *Clin Nucl Med.* 2018 Sep;43(9):635-640.
- Dirix V, Corbière V, Wyndham-Thomas C, Selis E, Allard S, Hites M, Aerts L, Giese T, Mascart F. Blood tolerogenic monocytes and low proportions of dendritic cell subpopulations are hallmarks of human tuberculosis. *J Leukoc Biol.* 2018 May;103(5):945-954.
- Thielemans E, Wyndham-Thomas C, Henrard S, De Vleeschouwer A, Steensels D, Montesinos I, Debaisieux L, Delforge ML, Van Vooren JP, Goffard JC. Screening for Chlamydia trachomatis and Neisseria gonorrhoeae Infections in Men Who Have Sex With Men: Diagnostic Accuracy of Nucleic Acid Amplification Test on Pooled Urine, Anorectal, and Pharyngeal Specimens. *Sex Transm Dis.* 2018 Mar;45(3):195-198.
- Masri R, Damade R, Al Gain M, Bouaziz JD, Wyndham-Thomas C. Cutaneous lesions in a 69-year-old woman. *Rev Med Interne.* 2017 Oct;38(10):704-707. doi: 10.1016/j.revmed.2017.06.018. Epub 2017 Jul 19. French. No abstract available.
- Gunter J, Callens S, De Wit S, Goffard JC, Moutschen M, Darcis G, Meuris C, van den Bulcke C, Fombellida K, Del Forge M, Razavi H, Wyndham-Thomas C. Prevalence of non-infectious comorbidities in the HIV-positive population in Belgium: a multicenter, retrospective study. *Acta Clin Belg.* 2017; 16:1-4
- Cheron J, Wyndham-Thomas C, Sadeghi N, Naeije G. Response of Human Immunodeficiency Virus-Associated Cerebral Angiitis to the Combined Antiretroviral Therapy. *Front Neurol.* 2017; 13;8:95.
- Wyndham-Thomas C, Dirix V, Corbière V, Selis E, Payen MC, Goffard JC, Van Vooren JP, Mascart F. Immune activation by Mycobacterium tuberculosis in HIV-infected and -uninfected subjects. *J Acquir Immune Defic Syndr.* 2017; 1;74(1):103-111.
- Henrard S, Wyndham-Thomas C, Van Vooren JP, Goffard JC. HIV infection : reaching a zero risk of transmission. *Rev Med Brux* 2016; 37 : 315-21
- Smits K, Corbière V, Dirix V, Mekkaoui L, Wyndham-Thomas C, Libin M, Dreesman A, Loyens M, Payen MC, Singh M, Loch C, Mascart F. Immunological Signatures Identifying Different Stages of Latent M. tuberculosis Infection and Discriminating Latent from Active Tuberculosis in Humans. *J Clin Cell Immunol* 2015; 6: 4
- Wyndham-Thomas C, Schepers K, Dirix V, Mascart F, Van Vooren JP, Goffard JC. Implementation of latent tuberculosis screening in HIV-care centres: evaluation in a low tuberculosis incidence setting. *Epidemiol Infect* 2015; 27:1-9.
- Wyndham-Thomas C, Dirix V, Schepers K, Martin C, Hildebrand M, Goffard JC, Domont F, Libin M, Loyens M, Loch C, Van Vooren JP, Mascart F. Contribution of a heparin-binding haemagglutinin interferon-gamma release assay to the detection of Mycobacterium tuberculosis infection in HIV-infected patients: comparison with the tuberculin skin test and the QuantiFERON-TB Gold In-tube. *BMC Infect Dis* 2015; 15:59
- Wyndham-Thomas C, Corbière V, Dirix V, Smits K, Domont F, Libin M, Loyens M, Loch C, Mascart F. Key Role of Effector Memory CD4+ T Lymphocytes in a Short-Incubation Heparin-Binding Hemagglutinin Gamma Interferon Release Assay for the Detection of Latent Tuberculosis. *Clin Vaccine Immunol* 2014; 21:321-328.
- Wyndham-Thomas C, Mulkay JP, Delforge M, Dr S. De Wit. Barriers to Liver Transplant in HIV-infected patients. *Acta Clin Belg.* 2013; 68(5):349-355.

[Projects](#)

[Memberships](#)

[Other Relevant Information](#)